Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12399]

Status:

Topic prioritisation

Technology type:

Medicine

Decision:

Not selected

Prioritisation programme:

Medicines evaluation

Rationale:

The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate your product is due to commissioning under the NHS England commissioning medicines for children in specialised services policy being appropriate with Dabrafenib being a paediatric extension of TA321.

ID number:

12399

Email enquiries

If you have any queries please email topic.selection@nice.org.uk

Timeline

Key events during the development of the guidance:

For further information on how we select topics for development, please see our page about topic prioritisation